Corvus Pharmaceuticals Announces Orphan Drug Designation ...

The US Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma.

FDA Grants Orphan Drug Designation to Soquelitinib in T-Cell ...

Corvus Pharmaceuticals announces orphan drug designation granted to soquelitinib for the treatment of T cell lymphoma. News release. · Song Y, ...

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical ...

... Orphan Drug Designation and Fast Track Designation by the FDA. BURLINGAME, Calif. , Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals ...

Corvus Pharmaceuticals Announces Orphan Drug Designation

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma. Company on track to ...

Corvus Pharmaceuticals Granted FDA Fast Track Designation for ...

In addition to Fast Track Designation, soquelitinib has also been granted FDA Orphan Drug Designation for the treatment of T cell lymphoma, ...

Press Releases - Corvus Pharmaceuticals

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma. Company on track to initiate ...

Press Releases | Corvus Pharmaceuticals

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma. Company on track to initiate ...

Corvus Pharmaceuticals Provides Business Update and Reports ...

There are no FDA fully approved agents for the treatment of relapsed PTCL and the FDA has granted soquelitinib Orphan Drug Designation for the ...

Corvus Pharmaceuticals Announces Orphan Drug Designation ...

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma. Rhea-AI Impact.

Corvus Pharmaceuticals Initiates Registrational Phase 3

... Orphan Drug Designation and Fast Track Designation by the FDA. BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, ...

FDA Grants Fast Track Designation to Soquelitinib for Relapsed ...

... corvus-pharmaceuticals-announces-orphan-drug-designation-granted; Corvus Pharmaceuticals confirms planned initiation of soquelitinib (CPI-818) ...

Corvus Pharma (CRVS) Granted FDA Orphan Drug Designation for ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for ...

Corvus Pharmaceuticals Announces Orphan Drug Designation ...

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T-cell lymphoma · BURLINGAME, Calif. · About ...

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

Corvus Pharmaceuticals, Inc. CRVS announced that the FDA granted the Orphan Drug Designation to its lead pipeline candidate, soquelitinib ...

Corvus Pharmaceuticals Granted FDA Fast Track Designation for ...

... drugs addressing serious conditions and unmet medical needs. Soquelitinib has also received FDA Orphan Drug Designation for T cell lymphoma ...

Corvus Pharmaceuticals Granted FDA Fast Track Designation for ...

In addition to Fast Track Designation, soquelitinib has also been granted FDA Orphan Drug Designation for the treatment of T cell lymphoma, ...

Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan ...

Corvus Pharmaceuticals said Thursday its candidate treatment for T cell lymphoma, soquelitinib, was granted orphan drug designation by the US Food and Drug ...

Corvus Pharmaceuticals Provides Business Update and Reports ...

... Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma. ... As recently announced, soquelitinib has received Fast Track ...

Search Orphan Drug Designations and Approvals - FDA

Orphan Designation Status: Designated. FDA Orphan Approval Status: Not FDA Approved for Orphan Indication. Sponsor: Corvus Pharmaceuticals, Inc. 863 Mitten ...

Corvus Pharmaceuticals Announces Orphan Drug Designation ...

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma. 9 months ago$CRVSHealth CareGlobeNewswire ...